Inflammatory bowel disease (IBD) is a general term for chronic or remitting/relapsing
inflammatory diseases of the intestinal tract and generally refers to ulcerative colitis (UC) …

Background Selective patient recruitment can produce discrepancies between clinical trial
results and real-world effectiveness. Methods A systematic literature review and meta …

OBJECTIVES: We aimed to quantify the safety and effectiveness of vedolizumab (VDZ)
when used for UC, and to identify predictors of response to treatment. METHODS …

Abstract The Asia–Pacific Working Group on Inflammatory Bowel Disease was established
in Cebu, Philippines, under the auspices of the Asia–Pacific Association of Gastroenterology …

Background There is no head‐to‐head trial comparing ustekinumab and vedolizumab in
patients with Crohn's disease (CD) refractory to anti‐tumour necrosis factor (anti‐TNF). Aim …

Leukocyte trafficking to the gastrointestinal tract is recognized to play a role in the
pathogenesis of inflammatory bowel disease (IBD). Integrins are expressed on immune cells …

Background Increased knowledge of pathways involved in the pathogenesis of IBD has led
to the development of new treatment options for Crohn's disease (CD) and ulcerative colitis …

Abstract Background and Aims Many inflammatory bowel disease (IBD) patients do not
respond to medical therapy. Tofacitinib is a first-in-class, partially selective inhibitor of Janus …

Background The effectiveness of vedolizumab as a treatment for extraintestinal
manifestations (EIM) is questionable due to its gut‐specificity. Aim To assess effectiveness of …

Background Anti‐tumour necrosis factor (TNF) agents are effective in Crohn's disease but
some patients lose response and require alternative biologic therapy. There are few data on …